MariMed Statement on Historic Rescheduling of Cannabis

NORWOOD, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- MariMed Inc. (“MariMed”) (CSE: MRMD) (OTCQX: MRMD), a leading multi-state cannabis operator committed to improving lives every day, issued the following statement from CEO Jon Levine today. “We commend President Trump and the Trump Administration for reclassifying cannabis as a Schedule III drug. This is the single greatest cannabis reform in US history and will have far-reaching benefits for years to come. Most important, the reclassification means the Fede ...